Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The cannabidiol implant is a patent-pending, biodegradable, long-acting subcutaneous delivery system developed by Qualthera Pharmaceuticals. Utilizing cannabidiol (CBD) as its active pharmaceutical ingredient, the implant is designed to provide sustained therapeutic levels of CBD over an extended period, addressing the low bioavailability and inconsistent absorption associated with oral and topical administration. The drug's mechanism involves the modulation of cannabinoid receptors (CB1 and CB2), antagonism of GPR55, and agonism of the 5-HT1A receptor. It is currently in early-stage development for the treatment of chronic pain and neurodegenerative conditions, specifically Alzheimer's disease and Parkinson's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol implant.